Schulman Associates IRB offers oncology-focused review board

Wednesday, June 27, 2012 03:46 PM

In response to the recent increases in oncology research conducted in North America, Schulman Associates IRB will offer a weekly board meeting of the new Schulman Oncology Board, dedicated to the review of oncology research, beginning July 23.

The new board's membership consists of a variety of oncology experts, who were carefully recruited from prestigious, nationally recognized research centers, and specifically selected based on their qualifications. Concentrations include pediatric oncology, radiation oncology, oncology research administration and more.

Oncology Board members will also lend their expertise to Schulman's regular Board meetings, as needed. Additional submission materials are not required to take advantage of the Oncology Board's services. Review turnaround times for the Oncology Board will remain consistent with Schulman's standard, competitive timelines.

"This enhanced Board expertise and dedicated additional Board meeting underscore Schulman's commitment to growth and improvement," said Michael Woods, Schulman's president and CEO. "We are delighted to be able to offer an unsurpassed level of service and expertise to our clients who are working to develop new cancer therapies and diagnostics."

The Oncology Board will review both industry-sponsored research as well as federally funded research. As with Schulman's other review boards, the Oncology Board will oversee research conducted at universities, hospital systems, community practices and other research sites.

Share:          
CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs